Improvements in eliciting dose across baseline sensitivities following 12?months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years.
Greenhawt M, Kim EH, Campbell DE, Green TD, Lambert R, Fleischer DM. Improvements in eliciting dose across baseline sensitivities following 12?months of epicutaneous immunotherapy (EPIT) in peanut-allergic children aged 4 to 11 years. J Allergy Clin Immunol Pract. 2020 10; 8(9):3219-3221.